BIRC5 and malignant glioma: The safety and efficacy of the neural stem cell delivered CRAd-Survivin-pK7 (NSC-CRAd-Survivin-pK7) under the survivin promoter were evaluated in the first human clinical trial of malignant glioma, in which the median progression-free survival was 9.1 months and the median overall survival was 18.4 months (Table 6) [30].